Across TCGA pan-cancer cohorts, OSBPL9 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated OSBPL9 data layer compared with 27 for mass-spec protein and 7 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher OSBPL9 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated OSBPL9 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
UCEC, LUAD, and HNSC are the cancer types where OSBPL9 Mutation most reproducibly stratifies survival.